Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03020550 · ClinicalTrials.gov registry record
Correlates of GERD Symptom Severity
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 24
- Enrollment target
NCT03020550: Completed study, sponsored by Massachusetts General Hospital.
NCT03020550 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03020550 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This is a pilot study measuring physiologic and behavioral correlates of symptom severity in adult patients with gastroesophageal reflux disease (GERD).
Primary Outcome
Galvanic skin response (GSR) was measured with a device from ADInstruments during the baseline study visit. Values ranged from 0.93 - 12 micro-Siemens (μS). Change in GSR was calculated as mean value of GSR for the first 2 minutes of the study visit minus mean value of GSR for the last 2 minutes of the study visit.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-05-22 |
| Est. Completion | 2019-05-07 |
What the finished NCT03020550 record still lists
NCT03020550 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03020550 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03020550 about?
NCT03020550 is a clinical study titled "Correlates of GERD Symptom Severity". This is a pilot study measuring physiologic and behavioral correlates of symptom severity in adult patients with gastroesophageal reflux disease (GERD).
What is the current status of trial NCT03020550?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2017-05-22. Estimated completion is 2019-05-07.
Who is sponsoring clinical trial NCT03020550?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI